[1]Graham DY,Fischbach L.Helicobacter pylori treatment in the era of increasing antibiotic resistance[J].Gut,2010,59(8):1143-1153.
[2]The European Helicobacter Study Group (EHSG).Management of Helicobacter pylori infectiondthe Maastricht Ⅳ/ Florence Consensus Report[J].Gut,2012,61(5):646-664.
[3]中华医学会消化病学分会幽门螺杆菌学组.第四次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志,2012,51(10):832-837.
[4]De Francesco V,Giorgio F,Hassan C,et al.Worldwide H.pylori antibiotic resistance:a systematic review[J].J Gastrointestin Liver Dis,2010,19(4):409-414.
[5]Song ZQ,Zhou LY.A study to explore Hp antibiotic resistance and efficacy of eradication therapy in China(Multi-Center,Nation-Wide,Randomized,Control study) [J].Helicobacter,2011,16(Supple 1):117. [6]薛艳,冯璜,周丽雅,等.根除幽门螺杆菌不同疗程及方案效果分析[J].中国实用内科杂志,2012,32(9):693-695.
[7]Furuta T,Graham D.Y.Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection [J].Gastroenterol Clin N Am,2010(39):465-480.
[8]Kubota T,Chiba K,Ishizaki T.Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population [J].Clin Pharmacol Ther,1996,60(6):661-666.
[9]Xie HG,Stein CM,Kim RB,et al.Allelic,genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world [J].Pharmacogenetics,1999,9(5):539-549.
[10]Zhao F,Wang J,Yang Y,et al.Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication:a Meta-analysis [J].Helicobacter,2008,13(6):532-541.
[11]Luther J,Peter DR,Phillip S,et al.Empiric Quadruple vs.Triple Therapy for Primary Treatment of Helicobacter pylori Infection:Systematic Review and Meta-Analysis of Efficacy and Tolerability [J].Am J Gastroenterol,2010,105(1):65-73.